Lifastuzumab vedotin, 1mg

Lifastuzumab vedotin, 1mg

Anetumab ravtansine, 1mg

Anetumab ravtansine, 1mg

Lifastuzumab vedotin, 1mg*5

19.336,31 RON
SKU
SKM_D4010_1mg*5

Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2bmonoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.

Mai multe informatii
Price 16.249,00 RON (preturile sunt fara TVA)
Description

Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2bmonoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.